SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-004387
Filing Date
2024-01-08
Accepted
2024-01-08 16:09:03
Documents
14
Period of Report
2024-01-07
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d609684d8k.htm   iXBRL 8-K 26367
2 EX-99.1 d609684dex991.htm EX-99.1 25290
6 GRAPHIC g609684g0108035540065.jpg GRAPHIC 2694
  Complete submission text file 0001193125-24-004387.txt   188790

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA annx-20240107.xsd EX-101.SCH 2846
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE annx-20240107_lab.xml EX-101.LAB 18756
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE annx-20240107_pre.xml EX-101.PRE 11707
8 EXTRACTED XBRL INSTANCE DOCUMENT d609684d8k_htm.xml XML 3469
Mailing Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005
Business Address 1400 SIERRA POINT PARKWAY BLDG C, SUITE 200 BRISBANE CA 94005 (650)-822-5500
Annexon, Inc. (Filer) CIK: 0001528115 (see all company filings)

IRS No.: 275414423 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39402 | Film No.: 24520157
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)